These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

444 related items for PubMed ID: 17965123

  • 1. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.
    Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP.
    Ann Rheum Dis; 2008 May; 67(5):713-6. PubMed ID: 17965123
    [Abstract] [Full Text] [Related]

  • 2. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC, Saxne T, Nilsson JA, Geborek P.
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [Abstract] [Full Text] [Related]

  • 3. Immune response to influenza vaccination in children treated with methotrexate or/and tumor necrosis factor-alpha inhibitors.
    Woerner A, Sauvain MJ, Aebi C, Otth M, Bolt IB.
    Hum Vaccin; 2011 Dec; 7(12):1293-8. PubMed ID: 22185812
    [Abstract] [Full Text] [Related]

  • 4. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor.
    Kobie JJ, Zheng B, Bryk P, Barnes M, Ritchlin CT, Tabechian DA, Anandarajah AP, Looney RJ, Thiele RG, Anolik JH, Coca A, Wei C, Rosenberg AF, Feng C, Treanor JJ, Lee FE, Sanz I.
    Arthritis Res Ther; 2011 Dec; 13(6):R209. PubMed ID: 22177419
    [Abstract] [Full Text] [Related]

  • 5. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity.
    Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podestà E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Laganà B, D Amelio R.
    Clin Immunol; 2010 Feb; 134(2):113-20. PubMed ID: 19846344
    [Abstract] [Full Text] [Related]

  • 6. Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study.
    Adler S, Krivine A, Weix J, Rozenberg F, Launay O, Huesler J, Guillevin L, Villiger PM.
    Rheumatology (Oxford); 2012 Apr; 51(4):695-700. PubMed ID: 22171015
    [Abstract] [Full Text] [Related]

  • 7. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.
    Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, Levartovsky D, Litinsky I, Kaufman I, Wigler I, Mendelson E, Elkayam O.
    Ann Rheum Dis; 2006 Feb; 65(2):191-4. PubMed ID: 16014674
    [Abstract] [Full Text] [Related]

  • 8. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
    Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, Comaneshter D, Levartovsky D, Mendelson E, Azar R, Wigler I, Balbir-Gurman A, Caspi D, Elkayam O.
    Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914
    [Abstract] [Full Text] [Related]

  • 9. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
    Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM.
    Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of decoy receptor- and antibody-mediated tumour necrosis factor blockage on FoxP3 expression in responsive arthritis patients.
    Ryder LR, Ryder LP, Bartels EM, Woetmann A, Madsen HO, Ødum N, Danneskiold-Samsøe B, Ribel-Madsen S, Bliddal H.
    APMIS; 2013 Apr; 121(4):337-47. PubMed ID: 23031059
    [Abstract] [Full Text] [Related]

  • 11. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, Mendelson E, Wigler I, Caspi D, Paran D.
    Semin Arthritis Rheum; 2010 Jun; 39(6):442-7. PubMed ID: 19246078
    [Abstract] [Full Text] [Related]

  • 12. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ.
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis.
    Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, Díaz-Cordovés G, López-Lasanta MA, Ponce A, Rodríguez-Pérez M, Calero E, González-Santos P.
    J Rheumatol; 2007 Dec; 34(12):2334-42. PubMed ID: 17985409
    [Abstract] [Full Text] [Related]

  • 14. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M, Turchini S, Parrochi P, Boccaccini P, Manetti R, Cammelli E, Manfredi M.
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [Abstract] [Full Text] [Related]

  • 15. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 16. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.
    Launay O, Abitbol V, Krivine A, Slama LB, Bourreille A, Dupas JL, Hébuterne X, Savoye G, Deplanque D, Bouhnik Y, Pelletier AL, Galtier F, Laharie D, Nachury M, Zerbib F, Allez M, Bommelaer G, Duclos B, Lucht F, Gougeon ML, Tartour E, Rozenberg F, Hanslik T, Beaugerie L, Carrat F, MICIVAX Study Group.
    J Crohns Colitis; 2015 Dec; 9(12):1096-107. PubMed ID: 26351392
    [Abstract] [Full Text] [Related]

  • 18. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D, Goëb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Ménard JF, Muraine M, Savoye G, Le Loët X, Tharasse C, Vittecoq O.
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [Abstract] [Full Text] [Related]

  • 19. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Isaacs JD.
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [Abstract] [Full Text] [Related]

  • 20. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ.
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.